You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to August 2024

AbstractFullPdf
Jun 20171700
Jul 20172600
Aug 20171800
Sep 20171800
Oct 20172805
Nov 20171302
Dec 20171300
Jan 20182803
Feb 20182100
Mar 20181800
Apr 2018600
May 2018600
Jun 20181000
Jul 20182400
Aug 2018600
Sep 2018800
Oct 2018400
Nov 2018601
Dec 2018600
Jan 2019601
Feb 2019400
Mar 2019401
Apr 2019504
May 2019603
Jun 2019802
Jul 2019603
Aug 2019402
Sep 2019201
Oct 2019602
Nov 2019402
Dec 2019400
Jan 2020400
Feb 2020801
Mar 2020401
Apr 2020401
May 2020804
Jun 20201200
Jul 20201002
Aug 20201006
Sep 20202707
Oct 20201201
Nov 2020600
Dec 2020601
Jan 2021001
Feb 2021607
Mar 2021001
Apr 2021204
May 2021100
Jun 2021104
Sep 2021003
Oct 20213014
Nov 20212012
Dec 2021201
Jan 2022001
Feb 2022400
Mar 2022002
Apr 2022801
May 2022805
Jun 2022403
Jul 2022601
Aug 20221204
Sep 2022403
Oct 2022605
Nov 2022200
Dec 2022400
Jan 2023202
Feb 2023200
Mar 2023800
Apr 2023001
May 2023003
Jun 2023200
Jul 2023202
Aug 2023002
Oct 2023200
Nov 2023200
Dec 20231804
Jan 2024201
Feb 2024201
Mar 20246028
Apr 20241008
May 2024804
Jun 2024603
Jul 2024603
Aug 20241402
Total6130192